Evidence map›Paper›PMID 37546850›Full record

ArticlebioRxiv : the preprint server for biology2023

Adapting antibacterial display to identify serum active macrocyclic peptide antibiotics.

Justin R Randall, Kyra E Groover, Angela C O'Donnell, Joseph M Garza, T Jeffrey Cole, Bryan W Davies

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Justin R RandallDepartment of Molecular Biosciences, University of Texas at Austin, Austin, Texas 78712.
Kyra E GrooverDepartment of Molecular Biosciences, University of Texas at Austin, Austin, Texas 78712.
Angela C O'DonnellDepartment of Molecular Biosciences, University of Texas at Austin, Austin, Texas 78712.
Joseph M GarzaDepartment of Molecular Biosciences, University of Texas at Austin, Austin, Texas 78712.
T Jeffrey ColeDepartment of Molecular Biosciences, University of Texas at Austin, Austin, Texas 78712.
Bryan W DaviesDepartment of Molecular Biosciences, University of Texas at Austin, Austin, Texas 78712.

Funding

Investigating nanobodies to target multidrug resistant bacterial pathogensR01AI148419 · NIAID · UNIVERSITY OF TEXAS AT AUSTIN · PI DAVIES, BRYAN WILLIAM · 2020 to 2023
$2.8M
A High-Throughput Molecular Platform for Antimicrobial Discovery and StudyR01AI125337 · NIAID · UNIVERSITY OF TEXAS AT AUSTIN · PI DAVIES, BRYAN WILLIAM · 2016 to 2020
$2.0M
Investigation of capsule interactions that promote antimicrobial peptide activityR21AI159203 · NIAID · UNIVERSITY OF TEXAS AT AUSTIN · PI DAVIES, BRYAN WILLIAM · 2021 to 2022
$429k
CLC NIH HHS C0000008NIAID NIH HHS R01 AI125337NIAID NIH HHS R01 AI148419NIAID NIH HHS R21 AI159203
6 · The paper itself

Abstract

The lack of available treatments for many antimicrobial resistant infections highlights the critical need for antibiotic discovery innovation. Peptides are an underappreciated antibiotic scaffold because they often suffer from proteolytic instability and toxicity towards human cells, making Significance: Traditional methods of natural antibiotic discovery are low throughput and cannot keep pace with the development of antimicrobial resistance. Synthetic peptide display technologies offer a high-throughput means of screening drug candidates, but rarely consider functionality beyond simple target binding and do not consider retention of function

Identifiers

PMID37546850
PMCPMC10402130

What OpenQuestion holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.